Bio-techne Corp · NASDAQ:TECH

Bio-techne — Investor Presentation (January 2026)

14 slides from Bio-techne's investor presentation, January 2026

Slide 2: Cautionary Statements
C A U T I O N A R Y S TAT E M E N T S This presentation contains “forward-looking Forward-looking statements are neither historical looking statement, whether written or oral, as statements” within the meaning of the federal facts nor assurances of future performance. a result of new information, fu
Slide 3: Confidential | © 2026 Bio-Techne ® ® . All rights reserved. | 3 Confidential
Confidential | © 2026 Bio-Techne®®. All rights reserved. | 3 Confidential | © 2026 Bio-Techne . All rights reserved. | 3
Slide 4: Our Segments and Product Portfolio
Headquarters Minneapolis, MN Number of Employees Our Segments and Product Portfolio 3,100 Instruments Worldwide Locations Protein Sciences: Consumables 9% Services 34 81% 7% Proteins Antibodies Immunoassays Royalties FY2025 Revenues 2% $1.2B Proteomic Cell Therapy FY2025 Revenues Analytical Instrume
Slide 5: Markets: Segments, End Markets and Geographies
Markets 13% Distributors Segments & Product End Markets 16% 51% Diagnostics Pharma/ Protein Sciences Diagnostics & Spatial Biotech Segment Biology Segment 20% Academia Spatial Biology 11% Precision Diagnostic 4% Tools* Core Diagnostic Geographies Core RUO 12% Controls** Reagents 41% & Assays** 27% E
Slide 6: Durable and differentiated product portfolio
Durable and differentiated product portfolio Balanced exposure to established and emerging applications across fast growing end-markets Portfolio leverage from leading protein/ antibody content Strong reputation as scientific leader Innovation to unlock high-growth opportunities Lean and nimble glob
Slide 7: Our portfolio creates leverage and applications drive growth
Our portfolio creates leverage and applications drive growth Our Strategic Growth Vectors We Enable Durable Applications Discovery of 1 Cell-Based Systems Novel Biological and Therapies Insights Proteins Antibodies Immunoassays Spatial Proteomic Analytical STAGES OF A PROGRAM Biology Instruments Dev
Slide 8: Starting Point and Leverage: Cell Therapy
1 Starting Point and Leverage Unmet Needs Innovation and Growth Runway Leading GMP portfolio for Industrialization of cell-therapy Innovation CAR T, Stem Cells based manufacturing: • High-performance AI Regenerative Medicine, and • Robustness designed proteins Organoids • Industrial form-factors • C
Slide 9: Starting Point and Leverage: Proteomic Analytical
2 Starting Point and Leverage Unmet Needs Innovation and Growth Runway Leading suite of proteomic Ease of use without Innovation analytical technologies compromising high sensitivity • New applications across and throughput • Simple Western , fully automated • Simple Western , Leo HT Cost-efficient
Slide 10: Starting Point and Leverage: Spatial Biology
3 Starting Point and Leverage Unmet Needs Innovation and Growth Runway Leading transcriptomic position Transcriptomic tools to support Innovation • RNAScope portfolio genomic medicine • Disease centric RNAScope • 75K probes across 450 species Standard of care for multiomic applications spatial inter
Slide 11: Addressable markets and growth
Discovery of Novel Biological Insights $14B TAM high-single digit growth Development and Manufacturing Enablement of of Advanced Therapeutics Precision Dx $5B TAM 20% growth $8B TAM mid-single digit growth Our core portfolio broadly addresses these markets and enables our leadership in key high-grow
Slide 13: Leveraging our core portfolio with broad access to strategic markets
Addressing $27B market growing Leveraging our Science-guided high-single digits core portfolio with identification of broad access to critical Durable position across high- strategic markets applications and value, high growth applications problems to solve Pursuing high-impact innovation priorities

Bio-Techne — Investor Presentation (January 2026) on 6ix

Bio-techne — Investor Presentation (January 2026)

Slide 1: Corporate Presentation January 2026

Slide 2: Cautionary Statements

Slide 3: Confidential | © 2026 Bio-Techne ® ® . All rights reserved. | 3 Confidential

Slide 4: Our Segments and Product Portfolio

Slide 5: Markets: Segments, End Markets and Geographies

Slide 6: Durable and differentiated product portfolio

Slide 7: Our portfolio creates leverage and applications drive growth

Slide 8: Starting Point and Leverage: Cell Therapy

Slide 9: Starting Point and Leverage: Proteomic Analytical

Slide 10: Starting Point and Leverage: Spatial Biology

Slide 11: Addressable markets and growth

Slide 12: Revenue and Adjusted Operating Income

Slide 13: Leveraging our core portfolio with broad access to strategic markets

Slide 14: Confidential | © 2026 Bio-Techne ® . All rights reserved. | 14